ESR1 and breast carcinoma: Taken together, these findings suggestd that stERAP-6 exhibited sustained inhibition of BIG3-PHB2 complex formation in tumours, thereby releasing PHB2 and allowing suppression of both genomic and non-genomic ERα activation along with E2-induced breast cancer growth in vivo.